Morgan Bayer

Articles

Real-World OS Outcomes Are Similar for Frontline CDK4/6 Inhibitor Combos in HR+, HER2– Breast Cancer

December 12th 2024

Retrospective data showed there was no OS difference between 3 frontline CDK4/6 inhibitor combos in HR-positive breast cancer.

SHR-A1811 Shows Initial Antitumor Activity, Tolerability in HER2+ Breast Cancer

December 11th 2024

SHR-A1811 monotherapy demonstrated high clinical activity and was well tolerated in patients with HER2-positive breast cancer.

Selinexor Plus Ruxolitinib Displays Activity in Ruxolitinib-Pretreated Myelofibrosis

December 11th 2024

Selinexor plus ruxolitinib showed activity in patients with myelofibrosis who were treated with ruxolitinib.

Pirtobrutinib Improves PFS in Previously Treated CLL/SLL

December 10th 2024

Pirtobrutinib improved progression-free survival in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma.

Navtemadlin Reduces Markers of Disease Burden in Relapsed/Refractory Myelofibrosis

December 9th 2024

Treatment with navtemadlin lowered the levels of biomarkers of disease burden in patients with relapsed/refractory myelofibrosis.

BTK Inhibitors, CAR T-Cell Therapy Drive Paradigm Changes in Follicular Lymphoma

November 13th 2024

Advancements in FL treatment, including BTK inhibitors and CAR T-cell therapies, offer new hope for relapsed or refractory cases.

Durvalumab/Tremelimumab Sustains OS Benefit in Unresectable HCC

September 16th 2024

Tremelimumab plus durvalumab sustained an overall survival improvement in unresectable hepatocellular carcinoma.

Ongoing Research Aims to Identify Treatment Approaches for Non–Clear Cell RCC Subtypes

July 12th 2024

Laurence Albiges, MD, PhD, discusses research evaluating treatments for subtypes of non–clear cell renal cell carcinoma.

Nivolumab Plus Ipilimumab and Chemo Maintains OS Benefit in NSCLC

June 4th 2024

Nivolumab plus ipilimumab and chemotherapy elicited a durable, long-term survival benefit vs chemotherapy alone in metastatic NSCLC.

Cilta-Cel Sustains MRD-Negative Responses in Previously Treated Multiple Myeloma

February 23rd 2024

Cilta-cel continues to elicit deep and durable responses in patients with early relapsed multiple myeloma, including those refractory to lenalidomide.

Ruxolitinib Plus Belumosudil Boosts Responses in Chronic GVHD

February 23rd 2024

Ruxolitinib and belumosudil demonstrated a beneficial ORR, indicating synergistic effects in targeting multiple inflammatory pathways in chronic GVHD.

Morphologic Type and Tumor Stage May Inform Real-World Outcomes in RCC

January 28th 2024

Real-world recurrence and prognosis was determined through the identification of morphologic RCC types and tumor stages.

Fostrox/Lenvatinib Combination Displays Efficacy, Tolerability in Pretreated HCC

January 19th 2024

Fostroxacitabine bralpamide plus lenvatinib displayed preliminary efficacy with a tolerable safety profile in patients with hepatocellular carcinoma.

NX-1607 Is Under Phase 1 Evaluation in DLBCL and Other Advanced Malignancies

December 11th 2023

The phase 1a/1b NX-1607-101 trial will evaluate NX-1607, a CBL-B inhibitor, in patients with advanced malignancies, including diffuse large B-cell lymphoma.

BDC-1001 Plus Pertuzumab Is Under Exploration in HER2+ Breast Cancer

December 6th 2023

The phase 2 BBI-20231001 trial evaluating the Boltbody immune-stimulating antibody conjugate BDC-1001 with or without pertuzumab in patients with HER2-positive breast adenocarcinoma is open for enrollment in the United States, France, Italy, and Spain.

Frontline VR-CAP Is Effective and Well Tolerated in MZL

October 23rd 2023

Bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride generated robust responses with a tolerable safety profile when delivered as first-line therapy in patients with marginal zone lymphoma.

Pirtobrutinib Maintains Efficacy and Decreases BTK C481 Clones Despite Acquired Resistance Mutations in CLL

October 9th 2023

Patients with chronic lymphoctyic leukemia treated with pirtobrutinib monotherapy experienced comparable objective response rates regardless of acquired BTK mutation and a decrease or clearance of BTK cysteine 481 clones despite the emergence of non-C481 clones or other less common mutations during or near the time of progression.

Physical Activity Improves Performance, Frailty Scores, and PROs in Multiple Myeloma

September 28th 2023

Exercises such as resistance training and walking were safe and effective interventions that were associated with improved frailty scores in patients with multiple myeloma receiving systemic treatment.

Durvalumab Associated With Lower Real-World PFS in EGFR-Mutated NSCLC Vs EGFR Wild-Type NSCLC

September 11th 2023

Treatment with durvalumab was associated with lower real-world progression-free survival in patients with unresectable, stage III EGFR-mutated non–small cell lung cancer vs patients with EGFR wild-type disease.